Caring for two in the ICU: Pharmacologic management of pregnancy-related complications.
critical care
drug therapy
obstetric
pregnancy
pregnancy complications
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
11
05
2023
received:
12
12
2022
accepted:
11
05
2023
medline:
13
7
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
Maternal mortality continues to be an issue globally despite advances in technology and pharmacotherapy. Pregnancy can lead to complications that necessitate immediate action to prevent severe morbidity and mortality. Patients may need escalation to the ICU setting for close monitoring and administration of advanced therapies not available elsewhere. Obstetric emergencies are rare but high-stakes events that require clinicians to have prompt identification and management. The purpose of this review is to describe complications of pregnancy and provide a focused resource of pharmacotherapy considerations that clinicians may encounter. For each disease state, the epidemiology, pathophysiology, and management are summarized. Brief descriptions of non-pharmacological (e.g., cesarean or vaginal delivery of the baby) interventions are provided. Mainstays of pharmacotherapy highlighted include oxytocin for obstetric hemorrhage, methotrexate for ectopic pregnancy, magnesium and antihypertensive agents for preeclampsia and eclampsia, eculizumab for atypical hemolytic uremic syndrome, corticosteroids, and immunosuppressive agents for thrombotic thrombocytopenic purpura, diuretics, metoprolol, and anticoagulation for peripartum cardiomyopathy, and pulmonary vasodilators for amniotic fluid embolism.
Substances chimiques
Metoprolol
GEB06NHM23
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
659-674Informations de copyright
© 2023 Pharmacotherapy Publications, Inc.
Références
Kassebaum NJ, Barber RM, Bhutta ZA, et al. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1775-1812. doi:10.1016/S0140-6736(16)31470-2
Anane-Fenin B, Agbeno EK, Osarfo J, et al. A ten-year review of indications and outcomes of obstetric admissions to an intensive care unit in a low-resource country. PLoS ONE. 2021;16(12):e0261974. doi:10.1371/journal.pone.0261974
Soares FM, Pacagnella RC, Tunçalp Ö, et al. Provision of intensive care to severely ill pregnant women is associated with reduced mortality: results from the WHO multicountry survey on maternal and newborn health. Int J Gynecol Obstet. 2020;150(3):346-353. doi:10.1002/ijgo.13241
Ragland D, Briggs GG, Wasik M, et al. Obstetrical opportunities: will pharmacy ever realize them? Ann Pharmacother. 2012;46(2):297-300. doi:10.1345/aph.1Q532
Briggs GG. Pharmacists in obstetrics. Am J Health Syst Pharm. 2018;75(3):92. doi:10.2146/ajhp170662
Liu C, Yu F, Xu Y, et al. Prevalence and risk factors of severe postpartum hemorrhage: a retrospective cohort study. BMC Pregnancy Childbirth. 2021;21(1):332. doi:10.1186/s12884-021-03818-1
Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011-2013. Obstet Gynecol. 2017;130(2):366-373. doi:10.1097/AOG.0000000000002114
Crozier TM, Wallace EM. Obstetric admissions to an integrated general intensive care unit in a quaternary maternity facility: obstetric ICU admissions in a quaternary maternity facility. Aust N Z J Obstet Gynaecol. 2011;51(3):233-238. doi:10.1111/j.1479-828X.2011.01303.x
Lankoande M, Bonkoungou P, Ouandaogo S, et al. Incidence and outcome of severe ante-partum hemorrhage at the teaching hospital Yalgado Ouédraogo in Burkina Faso. BMC Emerg Med. 2016;17(1):17. doi:10.1186/s12873-017-0128-3
Silver RM, Branch DW. Placenta accreta spectrum. N Engl J Med. 2018;378(16):1529-1536. doi:10.1056/NEJMcp1709324
Committee on Obstetric Practice. Committee opinion no. 529: placenta accreta. Obstet Gynecol. 2012;120(1):207-211. doi:10.1097/AOG.0b013e318262e340
Thurn L, Lindqvist P, Jakobsson M, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG. 2016;123(8):1348-1355. doi:10.1111/1471-0528.13547
Postpartum Hemorrhage. Practice bulletin no. 183: postpartum hemorrhage. Obstet Gynecol. 2017;130(4):e168-e186. doi:10.1097/AOG.0000000000002351
Tikkanen M. Placental abruption: epidemiology, risk factors and consequences: placental abruption, epidemiology. Acta Obstet Gynecol Scand. 2011;90(2):140-149. doi:10.1111/j.1600-0412.2010.01030.x
Escobar MF, Nassar AH, Theron G, et al. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynecol Obstet. 2022;157(S1):3-50. doi:10.1002/ijgo.14116
Al-Zirqi I, Daltveit AK, Forsén L, Stray-Pedersen B, Vangen S. Risk factors for complete uterine rupture. Am J Obstet Gynecol. 2017;216(2):165.e1-165.e8. doi:10.1016/j.ajog.2016.10.017
Hofmeyr GJ, Qureshi Z. Preventing deaths due to haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2016;36:68-82. doi:10.1016/j.bpobgyn.2016.05.004
Swank ML, Garite TJ, Maurel K, et al. Vasa previa: diagnosis and management. Am J Obstet Gynecol. 2016;215(2):223.e1-223.e6. doi:10.1016/j.ajog.2016.02.044
Oyelese Y, Catanzarite V, Prefumo F, et al. Vasa previa: the impact of prenatal diagnosis on outcomes. Obstet Gynecol. 2004;103(5):937-942. doi:10.1097/01.AOG.0000123245.48645.98
Masuzawa Y, Yaeko K. Uterine activity during the two hours after placental delivery among low-risk pregnancies: an observational study. J Matern Fetal Neonatal Med. 2017;30(20):2446-2451. doi:10.1080/14767058.2016.1253057
Rani PR. Recent advances in the management of major postpartum haemorrhage - a review. JCDR. 2017;11:QE01-QE05. doi:10.7860/JCDR/2017/22659.9463
Vallera C, Choi LO, Cha CM, Hong RW. Uterotonic medications. Anesthesiol Clin. 2017;35(2):207-219. doi:10.1016/j.anclin.2017.01.007
de Groot ANJA, van Dongen PWJ, Vree TB, Hekster YA, van Roosmalen J. Ergot alkaloids: current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs. 1998;56(4):523-535. doi:10.2165/00003495-199856040-00002
Sartain JB, Barry JJ, Howat PW, McCormack DI, Bryant M. Intravenous oxytocin bolus of 2 units is superior to 5 units during elective caesarean section. Br J Anaesth. 2008;101(6):822-826. doi:10.1093/bja/aen273
King KJ, Douglas MJ, Unger W, Wong A, King RAR. Five unit bolus oxytocin at cesarean delivery in women at risk of atony: a randomized, double-blind, controlled trial. Anesth Analg. 2010;111(6):1460-1466. doi:10.1213/ANE.0b013e3181f8930a
Carvalho JCA, Balki M, Kingdom J, Windrim R. Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstet Gynecol. 2004;104(5):1005-1010. doi:10.1097/01.AOG.0000142709.04450.bd
Methergine [package insert]. Novartis Pharmaceuticals, Corp; 2012.
Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynecol Obstet. 2007;99:S160-S167. doi:10.1016/j.ijgo.2007.09.004
Widmer M, Blum J, Hofmeyr GJ, et al. Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial. Lancet. 2010;375(9728):1808-1813. doi:10.1016/S0140-6736(10)60348-0
Vogel D, Burkhardt T, Rentsch K, et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol. 2004;191(6):2168-2173. doi:10.1016/j.ajog.2004.05.008
Hayashi RH, Castillo MS, Noah ML. Management of severe postpartum hemorrhage due to uterine atony using an analogue of prostaglandin F2 alpha. Obstet Gynecol. 1981;58(4):426-429.
Bygdeman M. Pharmacokinetics of prostaglandins. Best Pract Res Clin Obstet Gynaecol. 2003;17(5):707-716. doi:10.1016/S1521-6934(03)00043-9
O'Leary AM. Severe bronchospasm and hypotension after 15-methyl prostaglandin F2α in atonic post partum haemorrhage. Int J Obstet Anesth. 1994;3(1):42-44. doi:10.1016/0959-289X(94)90213-5
Butwick AJ, Carvalho B, Blumenfeld YJ, El-Sayed YY, Nelson LM, Bateman BT. Second-line uterotonics and the risk of hemorrhage-related morbidity. Am J Obstet Gynecol. 2015;212(5):642.e1-642.e7. doi:10.1016/j.ajog.2015.01.008
Pacheco LD, Clark SL, Klassen M, Hankins GDV. Amniotic fluid embolism: principles of early clinical management. Am J Obstet Gynecol. 2020;222(1):48-52. doi:10.1016/j.ajog.2019.07.036
Shakur H, Roberts I, Fawole B, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116. doi:10.1016/S0140-6736(17)30638-4
Combs CA, Montgomery DM, Toner LE, Dildy GA. Society for maternal-fetal medicine special statement: checklist for initial management of amniotic fluid embolism. Am J Obstet Gynecol. 2021;224(4):B29-B32. doi:10.1016/j.ajog.2021.01.001
Fitzpatrick KE, van den Akker T, Bloemenkamp KWM, et al. Risk factors, management, and outcomes of amniotic fluid embolism: a multicountry, population-based cohort and nested case-control study. PLoS Med. 2019;16(11):e1002962. doi:10.1371/journal.pmed.1002962
Ducloy-Bouthors A, Mercier F, Grouin J, et al. Early and systematic administration of fibrinogen concentrate in postpartum haemorrhage following vaginal delivery: the FIDEL randomised controlled trial. BJOG. 2021;128(11):1814-1823. doi:10.1111/1471-0528.16699
Hendriks E, Rosenberg R, Prine L. Ectopic pregnancy: diagnosis and management. Am Fam Physician. 2020;101(10):599-606.
ACOG. ACOG practice bulletin no. 191: tubal ectopic pregnancy. Obstet Gynecol. 2018;131(2):e65-e77. doi:10.1097/AOG.0000000000002464
Marret H, Fauconnier A, Dubernard G, et al. Overview and guidelines of off-label use of methotrexate in ectopic pregnancy: report by CNGOF. Eur J Obstet Gynecol Reprod Biol. 2016;205:105-109. doi:10.1016/j.ejogrb.2016.07.489
Practice Committee of the Society for Assisted Reproductive Technology. Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril. 2013;100(3):638-644. doi:10.1016/j.fertnstert.2013.06.013
Moore TJ, Walsh CS, Cohen MR. Reported medication errors associated with methotrexate. Am J Health Syst Pharm. 2004;61(13):1380-1384. doi:10.1093/ajhp/61.13.1380
Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-644. doi:10.1016/S0140-6736(10)60279-6
Gestational Hypertension and Preeclampsia. ACOG practice bulletin summary, number 222. Obstet Gynecol. 2020;135(6):1492-1495. doi:10.1097/AOG.0000000000003892
Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial. Obstet Gynecol. 1990;76(6):1070-1075.
Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol. 1994;171(3):818-822. doi:10.1016/0002-9378(94)90104-X
Committee on Obstetric Practice. Committee opinion no. 713: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2017;130(2):e102-e109. doi:10.1097/AOG.0000000000002237
Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database of Syst Rev. 2013;2013:CD001449. doi:10.1002/14651858.CD001449.pub3
Duley L, Gülmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. In: The Cochrane Collaboration, ed. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 2003:CD000025. doi:10.1002/14651858.CD000025
Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database of Syst Rev. 2010;2010:CD000127. doi:10.1002/14651858.CD000127.pub2
Belfort MA, Anthony J, Saade GR, Allen JC. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003;348(4):304-311. doi:10.1056/NEJMoa021180
Colditz PB, Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877-1890. doi:10.1016/S0140-6736(02)08778-0
Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet. 2000;38(4):305-314. doi:10.2165/00003088-200038040-00002
Okusanya B, Oladapo O, Long Q, et al. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG. 2016;123(3):356-366. doi:10.1111/1471-0528.13753
Dayicioglu V, Sahinoglu Z, Kol E, Kucukbas M. The use of standard dose of magnesium sulphate in prophylaxis of eclamptic seizures: do body mass index alterations have any effect on success? Hypertens Pregnancy. 2003;22(3):257-265. doi:10.1081/PRG-120024029
Alexander JM, McIntire DD, Leveno KJ, Cunningham FG. Selective magnesium sulfate prophylaxis for the prevention of eclampsia in women with gestational hypertension. Obstet Gynecol. 2006;108(4):826-832. doi:10.1097/01.AOG.0000235721.88349.80
Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. BJOG. 1998;105(3):300-303. doi:10.1111/j.1471-0528.1998.tb10090.x
Martin JN, Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol. 1999;180(6):1373-1384. doi:10.1016/S0002-9378(99)70022-0
Douglas KA, Redman CWG. Eclampsia in the United Kingdom. BMJ. 1994;309(6966):1395-1400. doi:10.1136/bmj.309.6966.1395
Duley L, Gülmezoglu AM, Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database of Syst Rev. 2010;2010:CD002960. doi:10.1002/14651858.CD002960.pub2
Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the collaborative eclampsia trial. Lancet. 1995;345(8963):1455-1463.
Dunn R, Lee W, Cotton DB. Evaluation by computerized axial tomography of eclamptic women with seizures refractory to magnesium sulfate therapy. Am J Obstet Gynecol. 1986;155(2):267-268. doi:10.1016/0002-9378(86)90805-7
Burrows RF, Kelton JG. Thrombocytopenia at delivery: a prospective survey of 6715 deliveries. Am J Obstet Gynecol. 1990;162(3):731-734. doi:10.1016/0002-9378(90)90996-K
Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynecol. 1990;162(2):311-316. doi:10.1016/0002-9378(90)90376-I
Tomsen TR. HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) presenting as generalized malaise. Am J Obstet Gynecol. 1995;172(6):1876-1880. doi:10.1016/0002-9378(95)91426-9
Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database of Syst Rev. 2010;(9):CD008148. doi:10.1002/14651858.CD008148.pub2
Fakhouri F, Scully M, Provôt F, et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020;136(19):2103-2117. doi:10.1182/blood.2020005221
George JN, Nester CM, McIntosh JJ. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology. 2015;2015(1):644-648. doi:10.1182/asheducation-2015.1.644
Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888-5897. doi:10.1182/blood-2012-02-408914
Delmas Y, Helou S, Chabanier P, et al. Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease. BMC Pregnancy Childbirth. 2015;15(1):137. doi:10.1186/s12884-015-0557-5
Stepanian A, Cohen-Moatti M, Sanglier T, et al. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. ATVB. 2011;31(7):1703-1709. doi:10.1161/ATVBAHA.111.223610
Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003;88(9):1029-1034.
Scully M, Thomas M, Underwood M, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211-219. doi:10.1182/blood-2014-02-553131
McCrae KR. Thrombocytopenia in pregnancy. Hematology. 2010;2010(1):397-402. doi:10.1182/asheducation-2010.1.397
Martin JN, Bailey AP, Rehberg JF, Owens MT, Keiser SD, May WL. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006. Am J Obstet Gynecol. 2008;199(2):98-104. doi:10.1016/j.ajog.2008.03.011
Goel A, Ramakrishna B, Zachariah U, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut. 2011;60(1):138-139. doi:10.1136/gut.2009.198465
Riviere E, Saint-Léger M, James C, et al. Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count: PLT transfusion for catheter insertion in TTP. Transfusion. 2015;55(7):1798-1802. doi:10.1111/trf.13041
Mahadevan U, Long MD, Kane SV, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021;160(4):1131-1139. doi:10.1053/j.gastro.2020.11.038
Shah S, Venkatesan RL, Gupta A, et al. Pregnancy outcomes in women with kidney transplant: metaanalysis and systematic review. BMC Nephrol. 2019;20(1):24. doi:10.1186/s12882-019-1213-5
Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499-1506. doi:10.1182/blood-2010-07-295444
Mariampillai AI, Garrison M, Zervoudakis AA. Rituximab for prevention of recurrent pregnancy related thrombotic thrombocytopenic purpura in high risk patients with previous episodes of thrombotic thrombocytopenic purpura during pregnancy. Blood. 2016;128(22):4940. doi:10.1182/blood.V128.22.4940.4940
Bruel A, Kavanagh D, Noris M, et al. Hemolytic uremic syndrome in pregnancy and postpartum. CJASN. 2017;12(8):1237-1247. doi:10.2215/CJN.00280117
Soliris (Eculizumab) [Prescribing Information]. Alexion Pharmaceuticals Inc; 2020.
Servais A, Devillard N, Frémeaux-Bacchi V, et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant. 2016;31(12):2122-2130. doi:10.1093/ndt/gfw314
Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018;93(2):450-459. doi:10.1016/j.kint.2017.06.022
Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681-696. doi:10.1016/S0140-6736(17)30062-4
Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29(4):319-329. doi:10.1097/QCO.0000000000000279
McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734-737. doi:10.15585/mmwr.mm6627e1
Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181. doi:10.1056/NEJMoa1208981
Sharma S, Thomas SS. Management of heart failure and cardiogenic shock in pregnancy. Curr Treat Options Cardio Med. 2019;21(12):83. doi:10.1007/s11936-019-0797-1
Mogos MF, Piano MR, McFarlin BL, Salemi JL, Liese KL, Briller JE. Heart failure in pregnant women: a concern across the pregnancy continuum. Circ: Heart Fail. 2018;11(1):e004005. doi:10.1161/CIRCHEARTFAILURE.117.004005
Banayan J, Rana S, Mueller A, et al. Cardiogenic shock in pregnancy: analysis from the national inpatient sample. Hypertens Pregnancy. 2017;36(2):117-123. doi:10.1080/10641955.2016.1242606
Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38(35):2671-2679. doi:10.1093/eurheartj/ehx355
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012
Honigberg MC, Givertz MM. Peripartum cardiomyopathy. BMJ. 2019;364:k5287. doi:10.1136/bmj.k5287
Buawangpong N, Teekachunhatean S, Koonrungsesomboon N. Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: a systematic review and meta-analysis. Pharmacol Res Perspect. 2020;8(5):e00644. doi:10.1002/prp2.644
Aldactone Package Insert, Rev. 2018.
Clark SL. Amniotic fluid embolism. Obstet Gynecol. 2014;123(2):337-348. doi:10.1097/AOG.0000000000000107
Fong A, Chau CT, Pan D, Ogunyemi DA. Amniotic fluid embolism: antepartum, intrapartum and demographic factors. J Matern Fetal Neonatal Med. 2015;28(7):793-798. doi:10.3109/14767058.2014.932766
Stafford IA, Moaddab A, Dildy GA, et al. Amniotic fluid embolism syndrome: analysis of the Unites States international registry. Am J Obstet Gynecol MFM. 2020;2(2):100083. doi:10.1016/j.ajogmf.2019.100083
Kaur K, Bhardwaj M, Kumar P, Singhal S, Singh T, Hooda S. Amniotic fluid embolism. J Anaesthesiol Clin Pharmacol. 2016;32(2):153-159. doi:10.4103/0970-9185.173356
Dado CD, Levinson AT, Bourjeily G. Pregnancy and pulmonary embolism. Clin Chest Med. 2018;39(3):525-537. doi:10.1016/j.ccm.2018.04.007
McDonnell N, Chan B, Frengley R. Management of critical haemodynamic complications of amniotic fluid embolism-in reply. Int J Obstet Anesth. 2008;17(2):190. doi:10.1016/j.ijoa.2007.09.007
Tran TT, Ahn J, Reau NS. ACG clinical guideline: liver disease and pregnancy. Am J Gastroenterol. 2016;111(2):176-194. doi:10.1038/ajg.2015.430
Cleveland Clinic: Cervix. Accessed December 1, 2022. Https://My.Clevelandclinic.Org/Health/Body/23279-Cervix
Cleveland Clinic: Placenta. Accessed December 1, 2022. Https://My.Clevelandclinic.Org/Health/Body/22337-Placenta